<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01379677</url>
  </required_header>
  <id_info>
    <org_study_id>2009Rb82UK</org_study_id>
    <secondary_id>2009-016645-25</secondary_id>
    <nct_id>NCT01379677</nct_id>
  </id_info>
  <brief_title>Rubidium-82 PET and Tc-99m-MIBI SPET: A Head to Head Comparison</brief_title>
  <official_title>Diagnosis of Coronary Artery Disease With Rubidium-82 PET and Technetium-99m-MIBI SPET: A Head to Head Comparison, Versus Coronary CT Angiography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advanced Accelerator Applications</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advanced Accelerator Applications</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare myocardial perfusion imaging using Rubidium-82
      PET with Tc-99m-MIBI SPET, in the evaluation of significant Coronary Artery Disease (CAD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The specificity of detecting significant coronary artery disease (as defined as being &gt;70% stenosis, on coronary CT angiography)</measure>
    <time_frame>Up to 2 days</time_frame>
    <description>The primary objective is to compare PET vs. SPET, with the primary outcome being the specificity of detecting significant coronary artery disease (as defined as being &gt;70% stenosis, on coronary CT angiography).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate any difference in the clinical interpretation of the Rubidium-82 PET and Tc-99m-MIBI SPET images.</measure>
    <time_frame>Up to 2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate any difference in &quot;Percentage myocardium&quot; that is hypoperfused, between Rubidium-82 PET and Tc-99m-MIBI SPET.</measure>
    <time_frame>Up to 2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate any difference in image quality, artefacts and interpretative confidence between Rubidium-82 PET and Tc-99m-MIBI SPET.</measure>
    <time_frame>Up to 2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate any adverse events or reactions, during Rubidum-82 or Tc-MIBI administration.</measure>
    <time_frame>Up to 2 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This is an Head to Head Comparison between Rubidium-82 PET and Tc-99m-MIBI SPET with CTA as gold standard. All the patients will undergo the three imaging protocols.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rubidium-82</intervention_name>
    <description>Maximum dose allowed per injection: 2200 MBq Maximum cumulated dose allowed per examination: 4400 MBq Intravenous Use</description>
    <arm_group_label>Single arm</arm_group_label>
    <other_name>CardioGen-82</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sestamibi. reconstitution with sodium pertechnetate (99mTc)</intervention_name>
    <description>Maximum dose allowed per injection: 1000 MBq Intravenous Use</description>
    <arm_group_label>Single arm</arm_group_label>
    <other_name>Technescan MIBI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Referred for scintigraphy to assess myocardial ischaemia

          -  Ability to give informed written consent.

        Exclusion Criteria:

          -  Impaired capacity to consent

          -  Pregnancy, or breastfeeding

          -  Allergy to iv contrast

          -  Renal failure

          -  Severe Uncontrolled asthma

          -  Claustrophobia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leon Menezes, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College Hospital London NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University College Hospital London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2011</study_first_submitted>
  <study_first_submitted_qc>June 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2011</study_first_posted>
  <last_update_submitted>May 13, 2014</last_update_submitted>
  <last_update_submitted_qc>May 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Myocardial perfusion imaging</keyword>
  <keyword>Rubidium</keyword>
  <keyword>Technetium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium Pertechnetate Tc 99m</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

